Skip to content

Dogwood Therapeutics DWTX Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
Bioventus logo
BioventusBVS
Avanos Medical logo
Avanos MedicalAVNS
LON
LeonaBio, Inc. Common StockLONA
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX

Other financials

Income statement

See full
Operating income-$5.1M-14.6%
Net income-$5.0M+54.4%
EPS (diluted)-$0.15+98.2%

Balance sheet

See full
Cash & equivalents$13.2M-24.6%
Total debt$144.9K-24.2%
Total equity$80.6M+1,038%
Total assets$95.2M-1.8%

Cash flow

See full
Operating cash flow-$4.6M+2.0%

Valuation

See full
Market cap$54.14M-57.6%
Enterprise value$41.06M-64.7%

Returns & leverage

See full
Return on equity-64.6%-29.8pp
Debt / equity0.0×
Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dogwood Therapeutics's operating lease right-of-use assets in other assets?
Dogwood Therapeutics (DWTX) reported operating lease right-of-use assets in other assets of $146.75K in Q1 2026.
How has Dogwood Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
Dogwood Therapeutics's operating lease right-of-use assets in other assets decreased by 24.3% year-over-year, from $193.76K to $146.75K.